⚡ Quick Start — If You Read Nothing Else
The 10 most important things to know right now.
- “Head and neck cancer” is really many different cancers. Where the cancer starts — mouth, throat (oropharynx), voice box (larynx), lower throat (hypopharynx), upper throat behind the nose (nasopharynx), salivary glands, or sinuses — changes the treatment and the outlook. Ask exactly which subsite you have.
- If it's in the throat/tonsil/base of tongue, ask whether it is HPV-positive. Many oropharyngeal cancers are caused by the human papillomavirus (HPV). HPV-positive throat cancer responds much better to treatment and has higher cure rates. Your tumor should be tested for a marker called p16/HPV, because it changes your stage and your outlook.
- Most head and neck cancer is curable — especially when found early. Early-stage disease is often cured with a single treatment (surgery alone or radiation alone). More advanced disease is frequently cured too, using combinations — often while preserving your voice and your ability to swallow.
- See a dentist BEFORE radiation. Radiation to the head and neck can cause a serious jaw bone complication (osteoradionecrosis). A dental check-up — with any needed extractions done before radiation starts — is one of the most important steps to prevent it. Do not skip it.
- You need a team, not one doctor. The best outcomes come from a multidisciplinary team: head and neck surgeon, radiation oncologist, medical oncologist, plus dentistry, speech-language pathology, and nutrition. Ask whether your case will be reviewed at a tumor board.
- Chemotherapy is often given with radiation, not instead of it. For locally advanced disease, the chemotherapy cisplatin given alongside radiation raises cure rates. A different drug, cetuximab, is used mainly when cisplatin can't be given — it is a fallback, not an equal substitute.
- Immunotherapy has changed advanced disease — and is now moving earlier. Drugs that release the brakes on the immune system (pembrolizumab, nivolumab) help many people with cancer that has come back or spread live longer. As of June 2025, pembrolizumab around surgery is FDA-approved for resectable locally advanced disease (the KEYNOTE-689 trial) — bringing immunotherapy into potentially curable disease.
- Nasopharyngeal cancer is its own disease. Cancer of the nasopharynx (upper throat behind the nose) is usually linked to the Epstein-Barr virus (EBV), is treated with chemotherapy and radiation (and now immunotherapy such as toripalimab), and can be monitored with a blood test for EBV DNA.
- “Gentler” treatment for HPV-positive cancer is still experimental. Researchers are testing lower-dose radiation and less chemotherapy to reduce long-term side effects. A major recent US trial (NRG-HN005) found the standard treatment still worked better. So de-escalation should only be done inside a clinical trial for now.
- Watch for emergencies and persistent symptoms. A sore in the mouth or throat that won't heal, a neck lump, ongoing hoarseness, painful or difficult swallowing, one-sided ear pain, or nasal blockage/bleeding lasting more than 2–3 weeks deserves prompt evaluation by an ENT. During treatment, trouble breathing, heavy bleeding from the mouth/throat, or inability to swallow your own saliva are emergencies.
📅 Your Action Clock — A Dated Checklist
Head and neck cancer is time-sensitive but, in most cases, not a same-day emergency. Use this as a rough calendar and adjust it with your team. The Ask lines are word-for-word questions you can read aloud.
- Within the first week of a suspicious symptom or abnormal finding: get an ENT (otolaryngologist) referral and a biopsy scheduled, and ask that the tumor be tested for p16/HPV (throat) or EBV (nasopharynx). Ask: "Is my tumor p16/HPV-positive, and how does that change my stage and my chances of cure?"
- Within two weeks of the biopsy: complete staging scans (CT/MRI and often a PET-CT) and request a multidisciplinary tumor-board review. Ask: "Given my subsite and stage, is surgery or chemoradiation the better first treatment for me, and why?"
- Before radiation begins (usually in the first two to three weeks of planning): see a dentist for evaluation and any needed extractions, plus a dietitian and a speech-language pathologist. This dental step helps prevent osteoradionecrosis and should not be skipped.
- In the first month of treatment: confirm the plan for controlling mouth and throat pain, for nutrition, and (if needed) for a feeding tube. Ask: "If I cannot receive cisplatin, is cetuximab my best alternative, and what do I give up in cure rate?"
- By month 3 after finishing treatment: expect a PET-CT to confirm the response, then a surveillance schedule (most intensive in the first 2 years). If disease is recurrent or metastatic, ask: "What is my PD-L1 (CPS) score, and does it point to immunotherapy alone or immunotherapy plus chemotherapy?"
Understanding Head and Neck Cancer
A diagnosis of head and neck cancer is frightening, and the words can be confusing — “squamous cell carcinoma,” “oropharynx,” “p16,” “CPS.” This guide is here to translate. Our goal is to help you understand what kind of cancer you have, what your choices are, and what questions to ask so you can get the best possible care.
Here is the single most important idea: head and neck cancer is not one disease. It is a family of cancers that start in different places — and the place where it starts, together with whether it is caused by a virus, changes everything about treatment and outlook. Two people can both have “throat cancer” and face completely different situations.
What “head and neck cancer” covers
Most head and neck cancers are squamous cell carcinomas — cancers that begin in the flat, skin-like cells lining the mouth and throat. They are grouped by subsite (where they start):
- Oral cavity — lips, front of the tongue, gums, floor of the mouth, inside of the cheeks, hard palate. Strongly linked to tobacco, alcohol, and (in parts of Asia) betel/areca-nut chewing.
- Oropharynx — tonsils, base (back) of the tongue, soft palate, and back wall of the throat. This is where HPV-related cancer usually arises.
- Larynx (voice box) — treatment here focuses heavily on preserving your voice when possible.
- Hypopharynx — the lower throat, behind and around the voice box.
- Nasopharynx — the upper throat behind the nose. A distinct cancer, usually linked to the Epstein-Barr virus (EBV), most common in parts of southern China and Southeast Asia.
- Salivary glands and sinuses/nasal cavity — less common and biologically different; treated somewhat differently (salivary gland cancers are often not squamous cell and follow their own rules).
How treatment fits together (the big picture)
Treatment depends on your subsite, your stage, and your HPV/EBV status, but the building blocks are:
- Surgery — removing the tumor, from minimally invasive transoral robotic surgery (TORS) for selected throat cancers, to larger operations with reconstruction.
- Radiation therapy — high-precision X-rays (intensity-modulated radiotherapy, IMRT; sometimes proton therapy) that can cure many head and neck cancers and help preserve organs like the voice box.
- Chemotherapy — usually cisplatin given together with radiation (“chemoradiation”) for locally advanced disease.
- Immunotherapy — checkpoint inhibitors (pembrolizumab, nivolumab) that unleash the immune system; standard for recurrent/metastatic disease, and now used around surgery in selected locally advanced disease.
- Targeted therapy — cetuximab, which blocks the EGFR protein, used in specific situations.
- Supportive and rehabilitative care — dental care, nutrition and feeding-tube support, speech and swallowing therapy, pain and dry-mouth management. These are core parts of treatment, not optional extras.
Getting Diagnosed
The path to diagnosis usually starts with a symptom that won't go away. Because head and neck cancers are often curable when caught early but harder to treat when advanced, persistent symptoms deserve prompt attention.
- A sore in the mouth or throat that doesn't heal, or a white/red patch in the mouth
- A lump in the neck (a very common first sign of HPV-related throat cancer)
- Persistent hoarseness or a change in your voice (especially >3 weeks — a key warning for larynx cancer)
- Pain or difficulty swallowing, or a feeling of something stuck in the throat
- Unexplained, persistent one-sided ear pain (referred pain from the throat)
- Nasal blockage or bleeding, or hearing loss/fullness in one ear (warning signs for nasopharyngeal cancer)
- A loose tooth, ill-fitting denture, or a lump on the gum or jaw with no dental cause
What the workup involves
Getting a clear diagnosis and stage usually takes several steps. This can feel slow, but each step shapes the treatment plan:
- Examination. The ENT examines your mouth and throat, often with a thin flexible scope passed through the nose to view the throat and voice box.
- Biopsy. A small tissue sample confirms cancer. For a neck lump, this may be a fine-needle aspiration. The tissue is also tested for p16/HPV (for throat cancers) and, when relevant, EBV (for nasopharyngeal cancers).
- Imaging. CT and/or MRI map the tumor and lymph nodes; a PET-CT scan checks for spread and for a second cancer. Imaging of the chest is common.
- Examination under anesthesia / panendoscopy. A more thorough look at the throat under anesthesia, sometimes done to find a hidden primary tumor or rule out a second cancer.
- Baseline dental and nutrition assessment. If radiation is likely, you'll see a dentist (to protect your jaw) and ideally a dietitian and a speech-language pathologist before treatment starts.
Prepare for your appointments
- Bring someone with you. A second set of ears is invaluable when a lot of information comes fast.
- Write down your questions in advance and ask permission to record the conversation.
- Ask for copies of your pathology report (including p16/HPV or EBV status), staging, and imaging.
- Track your weight, what you can eat and drink, pain levels, and any new symptoms in a simple log.
Types, Subsites & Staging
Staging describes how big the cancer is and whether it has spread. It uses the AJCC 8th-edition system, which combines three things — T (size/extent of the main tumor), N (lymph nodes in the neck), and M (spread to distant organs) — into an overall stage from I (earliest) to IV (most advanced). Your stage strongly shapes treatment.
The subsites at a glance
How stage maps to treatment intensity
- Early stage (I–II): usually one treatment — surgery alone or radiation alone.
- Locally advanced (III–IVA/IVB): usually combination treatment — chemoradiation, or surgery followed by radiation or chemoradiation; immunotherapy around surgery may be added in resectable disease.
- Recurrent or metastatic (IVC / cancer that returns or spreads): treatment shifts toward immunotherapy and chemotherapy to control the cancer and extend life, sometimes with salvage surgery or re-irradiation for cancer that comes back in one spot.
Early-Stage Treatment (Stage I–II)
For early-stage head and neck cancer, the encouraging news is that a single treatment is often enough to cure it. The two main options — surgery alone or radiation alone — usually offer similar chances of cure for early disease. The choice often comes down to which one best preserves your function (speech, swallowing) and fits your situation.
Surgery for early disease
Removing the tumor surgically can be definitive for early cancers. The approach depends on subsite:
- Oral cavity cancers are usually treated with surgery first.
- Selected oropharyngeal (throat) cancers can be removed through the mouth using transoral robotic surgery (TORS) or transoral laser surgery — no external incision, often faster recovery, and sometimes the chance to avoid or reduce radiation.
- Early larynx cancers can sometimes be treated with limited (organ-preserving) surgery that keeps the voice.
- The surgeon often also samples or removes neck lymph nodes (a neck dissection) to check for spread.
Radiation for early disease
Modern radiation — especially intensity-modulated radiotherapy (IMRT) — shapes the radiation dose precisely around the tumor while sparing nearby healthy tissue like the salivary glands. For many early cancers (including early larynx cancer), radiation alone offers excellent cure rates and can avoid surgery. Proton therapy is available at some centers and may further reduce dose to healthy tissue in selected cases.
Larynx (voice box) preservation
For early larynx cancer, preserving the voice is usually very achievable — with radiation or with limited surgery. The goal is to cure the cancer while keeping you able to speak and breathe normally. Your team should explicitly discuss how each option affects your voice.
Locally Advanced Treatment (Stage III–IVB)
“Locally advanced” means the cancer is larger and/or has spread to neck lymph nodes, but not to distant organs. This stage usually needs combination (multimodality) treatment — and, importantly, it is frequently curable. The two main roads are (1) chemoradiation, or (2) surgery followed by radiation or chemoradiation. Increasingly, immunotherapy is added around surgery.
Road 1: Definitive chemoradiation
For many locally advanced cancers — especially of the throat, larynx, and hypopharynx — the standard is radiation given together with the chemotherapy cisplatin (“concurrent chemoradiation”). Adding cisplatin to radiation meaningfully raises cure rates compared with radiation alone. The classic schedule is high-dose cisplatin every 3 weeks during radiation; some patients receive lower-dose weekly cisplatin instead, depending on fitness and tolerance.
Road 2: Surgery with risk-adapted radiation afterward
For some cancers (especially oral cavity, and selected throat cancers via TORS), surgery comes first. What's found at surgery then guides whether you need additional treatment:
- Favorable findings: surgery alone, or surgery plus radiation, may be enough.
- “Adverse features”: if the surgeon finds cancer at the edge of what was removed (positive margins) or cancer that has broken out of a lymph node (extranodal extension), then chemoradiation after surgery (chemo added to radiation) lowers the chance of recurrence. Other features (multiple involved nodes, nerve or vessel invasion) may call for radiation after surgery.
The big recent change: immunotherapy around surgery (KEYNOTE-689)
Locally advanced nasopharyngeal cancer
Nasopharyngeal cancer follows its own path. Locally advanced disease is typically treated with chemoradiation, often after induction chemotherapy (commonly gemcitabine plus cisplatin given first to shrink the cancer). Increasingly, immunotherapy is being integrated. Your team may use a blood EBV DNA level to help gauge risk and follow your response.
Recurrent, Metastatic & Immunotherapy
If head and neck cancer comes back after treatment (recurrent) or has spread to distant parts of the body (metastatic), the goal usually shifts from cure to controlling the cancer, extending life, and maintaining quality of life — though cure is sometimes still possible for cancer that returns in a single, treatable spot. This is the area where immunotherapy has made the biggest difference.
First-line treatment: the role of your PD-L1 (CPS) score
For most recurrent/metastatic squamous cell head and neck cancer, the first-line standard is based on the KEYNOTE-048 trial and depends on a tumor score called the PD-L1 combined positive score (CPS), which estimates how much the immune-checkpoint target is present:
- Higher CPS: pembrolizumab alone is often preferred — immunotherapy without chemotherapy.
- Lower CPS, or when faster tumor shrinkage is needed: pembrolizumab plus chemotherapy (a platinum drug plus fluorouracil) is used.
Both approaches improved survival compared with the older “EXTREME” cetuximab-chemotherapy regimen. Your CPS score is therefore an important number to ask about.
If cancer progresses after platinum chemotherapy
For cancer that worsens during or shortly after platinum-based chemotherapy, nivolumab (another checkpoint inhibitor) improved survival compared with standard chemotherapy in the CheckMate-141 trial, with responses that can last. Cetuximab-based combinations remain an option in some situations.
Recurrent/metastatic nasopharyngeal cancer
For recurrent or metastatic nasopharyngeal cancer, immunotherapy plus chemotherapy is now standard. In the US, toripalimab (with gemcitabine and cisplatin) is FDA-approved as first-line treatment, and as a single agent after platinum chemotherapy, based on the JUPITER-02 trial — the first PD-1 immunotherapy approved in the US for this disease. A second US option, penpulimab-kcqx, was FDA-approved in April 2025 — with platinum chemotherapy and gemcitabine for first-line recurrent or metastatic non-keratinizing nasopharyngeal cancer, and as a single agent after platinum chemotherapy plus at least one other treatment. (Other PD-1 drugs such as camrelizumab and tislelizumab are used in other regions.) Blood EBV DNA can help monitor the cancer.
Cancer that returns in one spot
When head and neck cancer comes back in a single, localized area (and hasn't spread widely), treatment with curative intent may still be possible — through salvage surgery or, in selected cases, re-irradiation. These decisions are complex and weigh the chance of cure against added side effects; they belong at an experienced multidisciplinary center.
Side Effects & Supportive Care
Head and neck cancer treatment can be hard on the very functions you use every day — eating, talking, breathing. The good news is that most side effects are expected, preventable, or treatable, and a strong supportive-care team makes treatment far more manageable. These services are part of your treatment, not extras.
During treatment (especially chemoradiation)
- Mouth and throat sores (mucositis). Painful inflammation of the lining of the mouth and throat, usually peaking in the later weeks of radiation. Managed with good mouth care, salt/baking-soda rinses, prescription mouthwashes, and pain medication (sometimes including opioids). Tell your team early — pain control protects your ability to eat and drink.
- Dry mouth (xerostomia). Radiation can damage salivary glands. Modern IMRT spares the glands much better than older radiation, and proton therapy may help further in some cases. Saliva substitutes, frequent sips of water, and prescription medicines can ease it; some dryness may persist long-term.
- Difficulty and pain swallowing (dysphagia). Swelling and soreness make swallowing hard. A speech-language pathologist teaches swallowing exercises — ideally started before and during treatment to keep the muscles working, which improves long-term swallowing.
- Weight loss and nutrition. Eating becomes a daily challenge. A dietitian helps maintain calories and protein; high-calorie liquids and soft foods help. Maintaining nutrition is critical to completing treatment.
- Taste changes, thick mucus, skin reactions, and fatigue are common and usually improve after treatment ends.
- Cisplatin side effects: can include kidney strain, hearing loss/ringing (ototoxicity), nausea, and low blood counts — monitored closely, with the schedule (every-3-weeks vs weekly) chosen partly to balance these.
The main drugs: doses, safety thresholds, and cost
Your oncologist always sets the exact dose for your body size and kidney function; the figures below are the standard reference doses so you know what to expect and what to ask about. Clear rules also govern when to stop or hold each drug.
- Cisplatin (chemotherapy given with radiation): typically 100 mg/m² every 3 weeks, or 40 mg/m² weekly, during radiation (per the NCCN Head and Neck Cancers guideline and the landmark chemoradiation trials). Stop rule: the FDA label for cisplatin states a repeat dose should not be given until the kidneys recover — serum creatinine below 1.5 mg/dL and/or BUN below 25 mg/dL. Hearing is tracked with audiograms; report new ringing or hearing loss.
- Cetuximab (Erbitux; the fallback when cisplatin cannot be used): per its FDA label, 400 mg/m² as a first (loading) dose, then 250 mg/m² weekly, with an antihistamine given 30–60 minutes before the first dose. Stop rule: the team will immediately interrupt and permanently discontinue if a serious (grade 3–4) infusion reaction occurs. Ask: "If I need cetuximab instead of cisplatin, what does that change about my chance of cure?"
- Pembrolizumab (Keytruda) and nivolumab (Opdivo) — immunotherapy for recurrent or metastatic disease, and, for pembrolizumab, around surgery: per their FDA labels, pembrolizumab is 200 mg every 3 weeks or 400 mg every 6 weeks, and nivolumab is 240 mg every 2 weeks or 480 mg every 4 weeks. Stop rule: for immune side effects the team holds the drug for a moderate (grade 2) reaction and permanently discontinue if the reaction is severe (grade 3–4), usually adding steroids (prednisone 1–2 mg/kg per day). Ask: "What immune-related side effects should make me call you the same day?"
What it costs (US, as of July 2026). The chemotherapy drugs are inexpensive generics: cisplatin runs about $40 (SingleCare cash price) up to an average retail price near $82.40, and carboplatin about $36 up to an average retail near $231 (SingleCare estimates, July 2026). The large costs are the brand immunotherapies (pembrolizumab, nivolumab) and cetuximab, which are given in a clinic and billed mostly under Medicare Part B or commercial medical insurance rather than at a pharmacy. Coverage path: ask the cancer center's financial navigator to run a benefit check, and contact the manufacturer assistance programs — Merck Access Program 855-257-3932 (Keytruda) and BMS Access Support 1-800-861-0048 (Opdivo) — which offer benefit investigation and co-pay help for eligible patients; the cetuximab maker (Lilly) runs a comparable program. Ask: "Can your financial navigator check my coverage and connect me to the manufacturer assistance program before treatment starts?"
Longer-term effects to watch for
- Persistent dry mouth and dental risk — lifelong fluoride and dental vigilance.
- Swallowing problems and aspiration — ongoing speech-therapy support; watch for coughing/choking with eating or signs of aspiration pneumonia (fever, productive cough, shortness of breath).
- Jaw stiffness (trismus) — stretching exercises and devices can help; start early.
- Neck/face swelling (lymphedema) — specialized lymphedema therapy helps.
- Underactive thyroid (hypothyroidism) after neck radiation — checked with periodic blood tests and easily treated.
- Carotid artery and other late effects — discussed and monitored as part of survivorship.
- Voice changes — speech therapy and, after laryngectomy, voice rehabilitation options.
Drug, Dose & Cost Reference
This section collects the standard reference doses, the rules for when a drug is held or stopped, and what treatment costs — so you know what to expect and what to ask. Your oncologist always sets your exact dose for your body size, kidney function, and hearing; the numbers below are the standard reference points from the FDA drug labels, the NCCN Head and Neck Cancers guideline, and the landmark trials. They are here to make you an informed partner, not to self-manage.
Treatment at a glance (dose, cost, and source)
| Drug | Standard dose | Typical US cost (July 2026) | Source |
|---|---|---|---|
| Cisplatin (with radiation) | 100 mg/m² every 3 weeks, or 40 mg/m² weekly | Generic: ~$40–$82.40 | FDA label; NCCN guideline; RTOG trials |
| Carboplatin (alternative) | Dosed by kidney function (AUC-based) | Generic: ~$36–$231 | FDA label; NCCN guideline |
| Cetuximab (fallback) | 400 mg/m² loading, then 250 mg/m² weekly | Brand; billed under Medicare Part B | FDA label; Bonner trial 2006; RTOG 1016 trial 2019 |
| Pembrolizumab | 200 mg every 3 weeks or 400 mg every 6 weeks | Brand; Part B; assistance available | FDA label; KEYNOTE-048 trial 2019; KEYNOTE-689 trial 2025 |
| Nivolumab | 240 mg every 2 weeks or 480 mg every 4 weeks | Brand; Part B; assistance available | FDA label; CheckMate-141 trial 2016 |
| Toripalimab (nasopharyngeal) | 240 mg every 3 weeks with chemotherapy | Brand; Part B | FDA label 2023; JUPITER-02 trial |
Part D out-of-pocket for any home pills is capped at $2,000 per year (2025 rule). Full details, hold/stop rules, and assistance phone numbers are below.
Chemotherapy given with radiation
| Drug | Standard reference dose | When it is held or stopped |
|---|---|---|
| Cisplatin (the main partner for radiation) | 100 mg/m² every 3 weeks during radiation (3 doses), or 40 mg/m² weekly. Concurrent cisplatin adds roughly a 6–7% improvement in long-term survival over radiation alone (MACH-NC analysis, 2009). | The FDA label says a repeat dose should not be given until the kidneys recover — serum creatinine below 1.5 mg/dL and/or BUN below 25 mg/dL. Hearing is checked with audiograms; report new ringing or hearing loss the same day. |
| Cetuximab (Erbitux; fallback only) | 400 mg/m² loading dose, then 250 mg/m² weekly, with an antihistamine 30–60 minutes before the first dose. | Stopped immediately and permanently for a severe (grade 3–4) infusion reaction; magnesium is monitored and often replaced. |
Immunotherapy drugs
| Drug | Standard reference dose | When it is held or stopped |
|---|---|---|
| Pembrolizumab (Keytruda) | 200 mg every 3 weeks or 400 mg every 6 weeks. Used for recurrent/metastatic disease and, since June 2025, around surgery (KEYNOTE-689). | Held for a moderate (grade 2) immune reaction; stopped permanently for a severe (grade 3–4) one, usually with steroids (prednisone 1–2 mg/kg per day). |
| Nivolumab (Opdivo) | 240 mg every 2 weeks or 480 mg every 4 weeks, for disease that worsened after platinum chemotherapy (CheckMate-141). | Same immune-reaction hold/stop rules as pembrolizumab. |
| Toripalimab (Loqtorzi; nasopharyngeal) | 240 mg every 3 weeks with gemcitabine–cisplatin, then on its own (JUPITER-02). | Same immune-reaction principles; blood EBV DNA may be followed alongside. |
Chemotherapy given before other treatment (induction)
For some cancers, chemotherapy is given first to shrink the tumor. The classic combination is TPF: docetaxel 75 mg/m² and cisplatin 75 mg/m² on day 1 plus 5-fluorouracil 750 mg/m² per day for 5 days, repeated every 3 weeks. For nasopharyngeal cancer, induction is usually gemcitabine 1000 mg/m² (days 1 and 8) with cisplatin 80 mg/m² every 3 weeks. Cisplatin acts as a radiosensitizer — the combined benefit of giving chemotherapy and radiation together (not one after the other) is what raises the cure rate.
When these drugs were approved (US FDA timeline)
Knowing the approval history helps you tell established standards from newer options. Each entry lists the drug, the year the FDA approved it for head and neck cancer, and the trial behind it (all consistent with the NCCN and ESMO guidelines):
- Nivolumab — FDA-approved 2016 for platinum-refractory disease (CheckMate-141 trial; Ferris et al, 2016).
- Pembrolizumab, first-line — FDA-approved 2019 for recurrent/metastatic disease, CPS-guided (KEYNOTE-048 trial; Burtness et al, 2019).
- Toripalimab — FDA-approved 2023 for nasopharyngeal cancer (JUPITER-02 trial; Mai et al, 2023).
- Penpulimab-kcqx — FDA-approved April 2025 for nasopharyngeal cancer (AK105-304 trial).
- Pembrolizumab around surgery — FDA-approved June 2025 for resectable locally advanced disease, CPS 1 or higher (KEYNOTE-689 trial; Uppaluri et al, 2025) — the newest and most practice-changing approval.
Cisplatin, cetuximab, and radiation are long-established standards defined by decades of trials (RTOG and EORTC trials, 2004–2019) and codified in the NCCN guideline and the FDA labels rather than by a single recent approval.
What treatment costs and how coverage works (US, July 2026)
The chemotherapy drugs themselves are inexpensive generics. Cash-price estimates (SingleCare, July 2026): cisplatin about $40 up to an average retail near $82.40; carboplatin about $36 up to an average retail near $231. The big costs are the brand immunotherapies (pembrolizumab, nivolumab, toripalimab) and cetuximab, which are infused in a clinic and billed under Medicare Part B or the medical side of commercial insurance — not at a pharmacy.
- Generic chemo (given with radiation): cisplatin ~$40–$82.40; carboplatin ~$36–$231. These are usually the least of your cost worries.
- Infused biologics/immunotherapy: billed under Medicare Part B (you generally owe 20% coinsurance unless you have supplemental coverage) or commercial medical benefit. Ask your center's financial navigator for a written benefit check before treatment starts.
- Any pills you take at home: if you have Medicare Part D, your out-of-pocket for covered drugs is now capped at $2,000 per year (2025, under the Inflation Reduction Act).
- Manufacturer help: Merck Access Program 855-257-3932 (Keytruda) and BMS Access Support 1-800-861-0048 (Opdivo) offer benefit checks and co-pay assistance for eligible patients; the cetuximab maker (Lilly) runs a comparable program.
Ask: "Can your financial navigator run a benefit check and connect me to the manufacturer assistance program before treatment starts?"
Word-for-Word Questions to Ask (Scripts)
These are ready-to-read questions. You can print them or read them aloud at your appointments.
- Ask: "Exactly which subsite is my cancer in, and is it HPV-positive (p16-positive) or HPV-negative?"
- Ask: "Is my treatment aimed at cure, and what are my realistic chances given my subsite, stage, and HPV status?"
- Ask: "Will I get cisplatin at 100 mg/m2 every 3 weeks or 40 mg/m2 weekly, and how will you protect my kidneys and hearing?"
- Ask: "If I cannot take cisplatin, is cetuximab my best alternative, and how much cure rate do I give up?"
- Ask: "Have I had my dental evaluation and any needed extractions scheduled before radiation begins?"
- Ask: "Will my radiation be IMRT, and is proton therapy an option to reduce dry mouth for me?"
- Ask: "Am I a candidate for pembrolizumab around surgery, and has my tumor's PD-L1 (CPS) score been tested?"
- Ask: "Will I see a speech-language pathologist to start swallowing exercises before treatment?"
- Ask: "Is a feeding tube likely, and will it be placed ahead of time or only if I need it?"
- Ask: "For my recurrent or metastatic cancer, what is my CPS score, and does it point to immunotherapy alone or with chemotherapy?"
- Ask: "For nasopharyngeal cancer, will you monitor my EBV DNA, and is toripalimab plus chemotherapy an option?"
- Ask: "What immune-related side effects should make me call you the same day?"
- Ask: "Am I eligible for any clinical trials, including gentler-treatment trials for HPV-positive cancer?"
- Ask: "Who do I call after hours, and what counts as an emergency (trouble breathing, heavy bleeding, or not being able to swallow my saliva)?"
Survivorship, Prevention & Resources
Finishing treatment is a milestone — and the beginning of a new phase. Survivorship focuses on watching for recurrence and second cancers, recovering function (swallowing, voice, dental health), managing long-term effects, and living well. Many people regain meaningful quality of life.
Follow-up and surveillance
- Regular check-ups with your team (more frequent in the first 2 years, when most recurrences occur, then spacing out) including exams of the mouth, throat, and neck.
- Imaging as indicated — often a PET-CT a few months after treatment to confirm response, then scans based on symptoms and exam.
- EBV DNA blood tests for nasopharyngeal cancer to watch for recurrence.
- Watch for second primary cancers. People with tobacco/alcohol-related head and neck cancer have a higher risk of new cancers elsewhere in the mouth, throat, esophagus, and lungs — another reason cessation matters.
- Lifelong dental care and thyroid checks after neck radiation.
- Report new symptoms promptly — a new lump, new pain, persistent hoarseness, or trouble swallowing.
Prevention — for you and your family
Clinical Trials
Clinical trials offer access to tomorrow's treatments today, and they drive the progress that has improved outcomes. Asking about trials is worthwhile at any stage and in any region.
- How to search: ClinicalTrials.gov is the main US/international registry — search by your condition and location. The WHO ICTRP portal (trialsearch.who.int) covers global trials. Ask your cancer center's research office and your oncologist directly.
- De-escalation trials (HPV-positive throat cancer): trials such as NRG-HN005 (NCT03952585) have tested gentler treatment; though that specific trial closed early in favor of standard treatment, the field is active — ask what is currently enrolling.
- Immunotherapy trials: the regimens behind today's standards came from trials like KEYNOTE-689 (NCT03765918, perioperative pembrolizumab), KEYNOTE-048 (NCT02358031, first-line recurrent/metastatic), CheckMate-141 (NCT02105636, platinum-refractory nivolumab), and KEYNOTE-040 (NCT02252042, second-line pembrolizumab). New combinations are constantly being tested.
- Nasopharyngeal cancer trials: the immunotherapy work behind JUPITER-02 (NCT03581786, toripalimab) and the penpulimab trial AK105-304 (NCT04974398).
- Surgery-based (TORS) de-escalation for HPV-positive throat cancer: ECOG-3311 (NCT01898494), ORATOR (NCT01590355), and ORATOR2 (NCT03210103) compared surgery-first and radiation-first paths and lower-dose radiation. These are why de-escalation remains a trials-only question.
- Radiation de-intensification trials (HPV-positive): NRG-HN002 (NCT02254278) and NRG-HN005 (NCT03952585) tested reduced-dose radiation; NRG-HN005 closed early because standard treatment stayed ahead.
- Trials that did not change practice (worth knowing so you recognize them): JAVELIN Head & Neck 100 (NCT02952586, avelumab added to chemoradiation — negative) and KEYNOTE-412 (NCT03040999, pembrolizumab added to chemoradiation — did not meet its goal).
Trial availability changes constantly; confirm current status on ClinicalTrials.gov or with your team.
Failed & De-adopted Therapies (Be Skeptical)
You'll encounter many claims online. Here are approaches that have not held up in rigorous testing, so you can recognize them:
- Cetuximab as an “equal” swap for cisplatin in HPV-positive cancer. Tested directly (RTOG 1016, De-ESCALaTE) and found inferior for cancer control. It's a fallback for people who can't take cisplatin, not an equivalent.
- De-escalation off-trial. Reducing radiation/chemo outside a clinical trial is not supported — NRG-HN005 showed standard treatment still won. Don't accept “less” treatment outside a trial just to reduce side effects.
- Adding certain immunotherapies to chemoradiation in locally advanced disease. Randomized trials adding checkpoint inhibitors to standard chemoradiation — avelumab in the JAVELIN Head & Neck 100 trial (Lee et al, Lancet Oncology 2021) and pembrolizumab in the KEYNOTE-412 trial (2022) — did not improve outcomes. (Perioperative pembrolizumab in the KEYNOTE-689 trial, 2025, is a different, positive story.)
- Nivolumab plus ipilimumab as first-line for recurrent/metastatic disease. The CheckMate-651 trial (2023) tested this dual immunotherapy against the older EXTREME regimen and did not meet its main survival goals — so CPS-guided pembrolizumab per the KEYNOTE-048 trial remains the standard.
- High-dose antioxidant supplements during radiation. A randomized trial (Bairati et al, 2005) found that high-dose vitamin E (alpha-tocopherol) during radiation was associated with worse cancer outcomes. Avoid high-dose antioxidant/herbal supplements during radiation unless your oncologist approves — some can interfere with treatment.
- “Alternative” cures in place of standard treatment. Replacing surgery/radiation/chemo with unproven alternatives costs precious time during a curable window. Complementary approaches for symptom relief can be fine — but discuss everything with your team, especially supplements (which can interact with chemo and immunotherapy).
Specialty Center Directory
Head and neck cancer outcomes are better at high-volume, multidisciplinary centers. Always verify current phone numbers and services, which can change.
International Access & Regulatory Landscape
Core treatments (surgery, radiation, chemoradiation, immunotherapy) are recommended by major guidelines worldwide (NCCN in the US, ESMO in Europe, and others), but access and timing of approvals differ:
- Pembrolizumab and nivolumab for recurrent/metastatic disease are widely approved (US FDA, EMA in Europe, PMDA in Japan, Health Canada, NICE in the UK, NMPA in China).
- Perioperative pembrolizumab (KEYNOTE-689) was FDA-approved in June 2025; approval and adoption in other regions (EMA, etc.) follow on their own timelines — ask whether it's available where you are.
- Nasopharyngeal-cancer immunotherapies reach regions at different times: toripalimab (FDA-approved 2023), camrelizumab, and tislelizumab were approved earlier in China; availability elsewhere varies.
- Advanced modalities — proton therapy, robotic surgery (TORS), and microvascular reconstruction — are unevenly available worldwide, which shapes organ-preservation options.
- Prevention and disease patterns differ: HPV-related throat cancer is rising in North America, Northern/Western Europe, and Australia; betel/areca-nut and smokeless-tobacco oral cancers are common in South/Southeast Asia; EBV-related nasopharyngeal cancer is endemic in southern China and Southeast Asia.
Glossary
Key References & Sources
For Caregivers: A Dedicated Toolkit
You are part of the care team. Head and neck cancer asks a lot of caregivers because it touches eating, speaking, and breathing. Here's a practical checklist:
- Side-effect management: support a strict mouth-care routine; keep pain medication on schedule (ahead of the sores); help manage dry mouth, thick mucus, and skin care.
- Nutrition & feeding tube: track weight, encourage high-calorie/high-protein intake, learn feeding-tube care if needed, and keep some swallowing going (as allowed) to protect the muscles.
- Appointments: expect many, across surgery, radiation, medical oncology, dentistry, speech therapy, and nutrition; keep a shared calendar and drive/attend when you can.
- Cessation support: help with quitting tobacco and alcohol — it improves treatment results and lowers second-cancer risk (1-800-QUIT-NOW).
- Rehabilitation: cue and join the daily swallowing and jaw-stretching exercises.
- Watch for emergencies: trouble breathing, heavy bleeding from the mouth/throat, inability to swallow saliva, signs of aspiration pneumonia (fever, cough, breathlessness) — seek urgent care.
- Emotional support: changes in appearance, voice, and eating are hard; listen, normalize, and connect to support groups (SPOHNC, Head and Neck Cancer Alliance).
- Care for yourself: caregiver burnout is real. Accept help, take breaks, and use the cancer center's social work and support services — they're for you too.
Fertility, Pregnancy & Head and Neck Cancer
HPV-associated head and neck cancers increasingly affect younger adults in their 30s and 40s. If you are of reproductive age, fertility and pregnancy planning deserve early attention.
Fertility preservation before treatment
- Before chemotherapy or radiation — cisplatin and other platinum-based drugs damage eggs and sperm. Radiation to the neck and head can affect the pituitary gland and thyroid (both of which are important for reproduction). Discuss fertility preservation before treatment begins: egg or embryo freezing (women), sperm banking (men).
- Radiation and gonads — for most head and neck cancers, the radiation field is not near the ovaries, so ovarian function is usually not directly affected. However, scatter radiation and pituitary involvement are possible; discuss with your radiation oncologist.
Pregnancy after head and neck cancer treatment
- Timing — most oncologists recommend waiting 2 years after completing treatment (the period of highest recurrence risk) before attempting pregnancy. Discuss your specific situation with your team.
- Thyroid monitoring — radiation to the neck commonly causes hypothyroidism over months to years. Thyroid hormone levels (TSH, free T4) should be checked and normalized before and throughout pregnancy, as untreated hypothyroidism is harmful to a developing baby.
- Nutritional status — treatment-related dysphagia, dry mouth (xerostomia), and weight changes must be addressed before pregnancy. Work with a dietitian to ensure adequate nutrition (especially folate, iron, and protein) throughout pregnancy.
- Checkpoint inhibitors (pembrolizumab, nivolumab) — these immunotherapy drugs must not be used during pregnancy. Effective contraception is required during treatment. If you are taking a checkpoint inhibitor and become pregnant, contact your oncologist immediately.
HPV vaccination and your family
If your cancer was HPV-associated, your partner and children of eligible age (up to 26 years; up to 45 years with shared decision-making) should be offered HPV vaccination to reduce their own future risk. Discuss with your primary care provider or oncologist.
Clinical Trials
Ask your care team whether a clinical trial is appropriate for your situation, and search ClinicalTrials.gov for current studies. See also the resources listed elsewhere in this guide.